Chicago Atlantic Real Estate Finance, Inc.

Good day and welcome to Chicago Atlantic Real Estate Financing First Quarter 2025 Warnings Conference Call. All participants will be in the listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference to Strip Sullivan with Investor Relations. Please go ahead.

Thank you. Good morning. Welcome to the Chicago Atlantic Real Estate Finance Conference Call to review the company's results. On the call today will be Peter Sack, Co-Chief Executive Officer, David Kite, Chief Operating Officer, and Phil Silverman, Chief Financial Officer. Our results were released this morning in our earnings press release which can be found on the Investor Relations section of our website along with our supplemental file with the SEC. A live audio webcast of this call is being made available today. For those who listened to the replay of this webcast, we remind you that the remarks made herein or as of today will not be updated subsequent to this call. During this call, certain comments and statements we make may be deemed forward-looking statements within the meeting prescribed by the securities laws including statements related to the future performance of our portfolio, our pipeline of potential loans, and other investments, future dividends, and financing activities. All forward-looking statements represent Chicago Atlantic's judgment as of the date of this conference call and are subject to risk and uncertainties that can cause extra results to differ materially from our current expectations. Investors are urged to carefully review various disclosures made by the company including the risk and other information disclosed in the company's filings with the SEC. We also will discuss certain non-GAP measures including but not limited to distributable earnings. Definitions of these non-GAP measures and reconciliations to the most comparable GAP measures are included in our filings with the SEC. I'll now turn the call over to Peter Sack. Please go ahead.

Thank you, Tripp. Good morning, everyone. At Chicago Atlantic, we place credit and collateral first and seek to add value to our borrowers through collaboration in an evolving industry. We are a leader in cannabis lending with a team of industry experts, originators, and underwriters. From day one, we have underwritten our portfolio assuming that the regulatory environment at the federal level does not improve. We've seen the gyrations that occur in the cannabis equity markets as optimism surrounding federal reform ebbs and flows. We seek to provide our investors downside protected returns and consistent yield regardless of fleeting sentiment and related equity volatility. That same volatility drives other capital providers to exit or scale back their presence. Amid this industry uncertainty, we believe Chicago Atlantic is a constant that borrowers and investors can count on. We deploy capital with consumer and product-focused operators in limited license jurisdictions at low leverage profiles to support fundamentally sound growth initiatives. In some quarters, that means that originations are at a strong pace and others like Q1 are at a slower pace. Investments are driven by credit and our ability to protect principle and achieve strong risk adjusted returns. If those opportunities aren't there for a period of time, we believe that the right decision is to be disciplined and patient. The cannabis pipeline across the Chicago Atlantic platform now stands at 462 million. There continue to be a number of well-run and well-capitalized operators that will need to address upcoming maturities over the next 12 months and we believe we will earn our fair share of those opportunities. As you've heard me say before, our goal is to create a differentiated and low-levered risk return profile that is insulated from cannabis equity volatility and outperforms our industry-agnostic mortgage-rate peers. Updating the analysis we provided last quarter, I'm pleased to note that despite all of the volatility in the broader financial services market, we remain the number three top-performing exchange-listed mortgage-rate. We have a slide in our supplemental that walks through this analysis. We're quite proud of this achievement and have our sights set on being number one. I'll close with the statistics. Since our inception, we've outperformed the median and average total return for all exchange-listed mortgage rates by approximately 51% and 55% respectively. David, why don't you take it from here?

Thank you, Peter. As of March 31, our loan portfolio principal totaled $407 million across 30 portfolio companies with a weighted average yield to maturity of .9% compared with .2% for the fourth quarter, primarily due to the restructuring of loan number nine. Gross originations during the quarter were $4.4 million of principal fundings, of which $0.5 million and $3.9 million was funded to new and existing borrowers on delayed draw term loan facilities respectively. These were offset by sales and repayments of $9.2 million. As of March 31, 2025, the percentage of our portfolio comprised of fixed-rate loans and fixed-rate loans were equal to the prevailing prime rate with 71.2%. The other .8% of the portfolio that remains floating is not exposed to interest rate caps at current levels. While the rate outlook is still uncertain due to the volatility Peter referenced earlier, we believe we have positioned the portfolio to limit the impact of interest rate declines and benefits should interest rates rise by adjusting the mix of floating and fixed-rate loans and negotiating high floors. Total leverage equaled 28% of book equity at March 31 compared with 34% at December 31, 2024. Our debt service coverage ratio on a consolidated basis for the quarter was approximately 6.2 to 1 compared to a requirement of 1.35 to 1. As of March 31, we had $38 million outstanding on our senior secured credit facility and had fully drawn down $50 million on our unsecured term loan. As of today, we have approximately $43 million outstanding on the senior credit facility and total liquidity of $65 million. Lastly, I'd like to provide an update on loan number nine. As we discussed last quarter, the administrative agent completed key milestones in the foreclosure on select operating assets of the borrower of loan number nine. Members of the administrative agent, which are related parties, were successfully affiliated with the Pennsylvania Department of Health as principals, giving them full operational control of these assets for benefit of the lenders. The aggregate proceeds from the foreclosure, which included the equity acquired via the UCC Article IX sale and the court-ordered judgment awarded, was distributed by the agent to the company and the other co-lenders. Given the company's restriction from holding equity investments in plant-touching cannabis operations, the company acquired new loans totaling approximately $16.5 million, which remained senior secured by the borrower's real estate assets and accrued interest at a fixed rate of 9%. The borrower's three dispensaries, which were previously non-operational, are now open, with the most recent opening occurring on April 30. REFI's new loan is senior secured and at the top of the capital structure. Given the senior secured nature of the restructured assets in the commencement of operations, we reverse approximately $1.2 million of the CISO Reserve related to loan number nine. It will take some time to get the operations where they need to be, but we hope that through this operational and balance sheet restructuring, we may restore this loan to accrual status this year.

I'll

now turn it over to Phil.

Thanks, David. Our net interest income of $13 million for the first quarter represented a .3% decrease from $14.1 million during the fourth quarter of 2024. The decrease was primarily attributable to the decrease in non-recurring prepayment, make-hole, exit and structuring fees, which amounted to $0.4 million for Q1 2025, compared with $1.5 million for Q1 2025, as well as the full quarter's impact of the 50 basis point decreases in the prime rate from the back half of the fourth quarter. Total interest expense, including non-cash amortization of financing costs for the first quarter, was consistent with Q4 2024 at approximately $2.1 million. The company incurred a full quarter of interest expense on our unsecured notes, which closed in mid-October last year and bear interest at 9%. The weighted average borrowings on our revolving loan, which bear interest at the prime rate plus an applicable margin based on our leverage ratio, increased to $41.6 million from $23.3 million during the fourth quarter. As of today, there's approximately $67 million available on our revolving loan. Total professional fees and general administrative expenses decreased quarter over quarter by approximately $300,000, primarily due to expense reimbursements to our manager, which were approximately $1.1 million for Q1 compared to $1.4 million in the prior quarter. Our Cecil Reserve on our loans held for investment as of March 31, 2025, was approximately $3.3 million compared with $4.4 million as of December 31, 2024. The decrease in reserves was primarily attributable to the reversal of $1.2 million of credit loss relating to loan number nine, which was restructured in Q1 2025, as David discussed. On a relative size basis, our reserve for expected credit losses represents 83 basis points of outstanding principle of our loans held for investment. On a weighted average basis, our portfolio maintained real estate coverage of 1.1 times. Our loans are secured by various forms of other collateral in addition to real estate, including UCC-1 all-asset liens on our borrower credit parties. These other collateral types contribute to overall credit quality and lower -to-value ratios. Our portfolio is a -to-enterprise value ratio of .5% as of March 31, 2025, calculated as senior indebtedness of the borrower divided by the fair value of total collateral. During the first quarter, we raised approximately $1 million of net proceeds from issuance of common stock through our ATM program. The weighted average selling price net of commissions of $15.69 represents a premium to our $1.5 million, a March 31 book value of approximately 5.5%. Distributable earnings per weighted average share on a basic and fully diluted basis was approximately $0.47 and $0.46 for the first quarter, which is consistent with the fourth quarter of last year. In April, we distributed the first quarter dividend of $0.47 per common share declared by our board in March 2025. Our book value was $14.87 and $14.83 per common share as of March 31, 2025, and December 31, 2024 respectively. On a fully diluted basis, there were approximately 21.3 million common shares outstanding as of March 31, 2025. As we shared on our call last quarter, we are expecting to maintain a dividend payout ratio based on our basic distributable earnings per share of 90% to 100% for the 2025 tax year. If our taxable income requires additional distributions in excess of the regular quarterly dividend to meet our taxable income requirements, we would expect to meet that requirement with a special dividend in the fourth quarter. Operator, we're now ready to take questions.

Thank you. We will now begin the question and answer session. To ask a question, you may press star then 1 on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star

then

2.

Our first question

comes from the line of Aaron Gray from Alliance Global Partners. Please go ahead.

Good morning and thank you very much for the questions here. First question for me, just in terms of the near-term pipeline, 462 million you guys had there, so it remains healthy. I just want to know if you can speak to how many are in there, how many are in the pipeline, and what stages they're in, how many are in the later stages if we can get a better sense of how we think that translates into new originations in 2025. I know you don't provide guidance, but maybe even some incremental color on the types of appealing opportunities you're seeing from that pipeline, whether or not they're more so capex bills or M&A, any color there will be appreciated. Thank you.

Thanks for the question. So, pipeline

is generally related to capex. We expect deployments to accelerate in Q2 and Q3 this year, but it's difficult

to get further detail beyond that. Okay, no, great. That's helpful there.

Thanks, Peter. Take what's really kind of high level one. Pricing pressure is something that continues to be a meaningful factor for the industry. As you're doing your underwriting, what are some of the pricing assumptions you're making, and is becoming a greater factor as we've seen some once-limited licensed markets, such as Massachusetts Mature, and we try some levels similar to open licensed markets. I'm just curious if you've adjusted the pricing that you make, the pricing assumptions you make in your underwriting versus you might have a year or two ago. Thank you.

It's interesting. We've always considered pricing in the industry to be evolving, and that in all states, there is a curve of development, the pricing that changes as a state begins its medical program. Even a limited license state begins its medical program, launches adult use, and that adult use program matures. And nearly every jurisdiction has some form, some downward slope of price compression. It's simply that in some states, that price compression is much slower than others. In the case of Massachusetts, as an example, over the past years, we've significantly but gradually reduced our exposure to a state like Massachusetts because we saw the pricing pressure on the horizon. That's one of the benefits that we as a lender, one of the levers that we as a lender have operating in this industry, where an operator would be less flexible. With our relatively short duration loans, we have opportunities to accept the maturity, get paid back, and then not deploy new capital into XYZ state. And it's much more difficult for an operator to do that. And so, as we are, when we look to deploy existing pricing and where we think that state sits in its progression of price compression is a key factor in terms of how we think about leverage and how we think about risk, and to the extent that we can diversify that all

the better.

Okay, great. That's a really helpful call. I appreciate it. I'll go ahead and drop it in the queue.

Thank you. The next question comes from Chris Mueller from JMP Securities. Please go ahead.

Hey guys, thanks for taking the questions. So maybe following up on that first question a little bit, how much visibility do you guys have into repayments in the near term? And should we expect to see some net portfolio growth in 2025? And I'm not looking for any specifics there, maybe just a general trend.

Our aim is to have net portfolio growth in 2025. There are a significant number of maturities in 2025, most of which we will be competing to refinance and to keep the relationship with the borrower, as we believe that the assets are performing strong, the companies have delevered or have strong attractive opportunities to either provide additional capital or to maintain a lending relationship with them. And so our aim for the vast majority of maturities in 2025 will be to compete to win the business and refinance those positions with new facilities.

That's very helpful. And then I know this comes up a lot and probably sounds like a broken record at this point, but it seems like rescheduling talks are picking up again following some comments from the new DEA nominee. So I guess from a high level, can you guys just talk about how rescheduling would impact your business if it actually does get done?

I think we'd like to see rescheduling and we'd like to see greater clarification of how past due tax liabilities from prior years will be treated going forward. Clarity on both of those would be highly accretive for what we do. For rescheduling, the elimination of 2ADE on a go-forward basis increases the after tax-free cash flow of all of our borrowers significantly. It allows them, it increases the downside protection of our debt facilities. It provides greater capital for growth, provides more equity value and equity dollars and cash flow that can support additional leverage and should accrete to equity valuations of the market at large, which we hope would then lead to greater activity of M&A, of capital expenditures and overall eliminate general market uncertainty that exists today. At the same time, while we think rescheduling is likely to lead to much more expansion and opportunity and expansion of valuations and growth of participants in the equity markets of cannabis, we think that greater participation of other lenders and debt capital in the cannabis space will take much more time and require greater reforms than simply rescheduling.

Got it. Maybe over a longer period of time, would you expect yields to generally compress but leverage would move up to kind of move towards that more typical mortgage rate model?

You know, I think we have to, you have to see additional entrants coming to the market in order to lead to yields compressing. And I have yet to see significant evidence of significant new entrants to the market simply on the basis of rescheduling. But we'll see.

It's a great setup for the people already in the space and you guys are doing a great job. Thanks for taking the question.

I think so. Thanks. And I guess I'd add that I think that I think that some of the largest publicly traded operators will probably be the best. The first to benefit from rescheduling and lower cost of capital, especially equity capital. I think that the next tier of middle market companies and lower middle market growing companies operating the space, it will take more time for capital providers, if any, do come to provide significant new options for that size and profile of operator.

Thanks a lot. Thanks for taking the questions again.

Thank you. The

next question comes

from Pablo

Zuanick

from Zuanick. Please go ahead.

Thank you. Good morning, everyone. Look, sorry to go back to the question about net portfolio growth. But, you know, new fundings for the thank you in the first quarter, I think about four million. You did 161 million the full year last year, almost more than almost 85 in the fourth quarter. I mean, that's a big change in terms of numbers, right? Does that mark does that imply that you become more cautious on the industry outlook, you know, over the next last three months or last six months or or or not necessarily. And then the the second question is, if you're not going to guide for portfolio growth, you know, what should we be assuming for the full year? I mean, just basic, very limited portfolio growth. If you can just add more color there, please. Thank you. Thank you, Pablo.

We are seeking to grow the portfolio to grow the portfolio meaningfully throughout the year. Q1 was a quarter of limited deployment, I think, driven by driven by two factors. One, the selectivity on our part and two is selectivity and not selectivity, it was caution and and. And greater consideration among operators in the whole industry, we saw in Q4 and Q1, some of the lowest valuations of cannabis public equities that that the markets ever seen. And I think that's led a lot of operators to think about their capital planning needs, think about their growth, think about their growth projects and wait to see if some items of uncertainty in the market change before making that next decision. And so I think it is a both a combination of caution and selection on our side and and. Caution and selection on the part of operators in this space in light of uncertainty in the industry.

It makes sense to that that's helpful color. I haven't finished going through it. Thank you. But can you talk about the unfunded commitments

for the quarter? Phil, would you like to take that? Yes,

yeah, sure. Hey, Pablo, we have about 19.8 million of unfunded commitments. Those are earmarked pursuant to the credit agreements in certain cases related to construction milestones or other projects that each of the borrowers are thinking about in the future. So we only deploy those if the conditions are met and in some cases, there are discretionary considerations that that we as Blunder can make before deploying those. So I think it's a little bit uncertain in terms of timing of when those may be deployed. Thank you.

Look, I'm going to make a parallel with sale this bag, and I understand it's a whole different industry. You know, we saw the IAPR Pharma Cannon situation. I think IAPR was very concerned about whether negotiating there would set a precedent. I understand restructuring for the mortgage read are part of the business, right? But that's the way that you restructure loan number nine, set a bit of a precedent for other credits in your portfolio from the

borrower perspective. I think I think every situation is every

situation is unique. That being said, with loan number nine, I think we showed that we as lenders are capable of completing a restructuring, bringing it to its full conclusion and supporting the operations of the business during the restructuring and coming out of the restructuring. And that we're willing to do so when we need to. And I think it shows that lending in the cannabis space, even with uncertainties around not having access to bankruptcy courts, can still be executed in the way that you would expect to be able to execute in downside scenarios.

Right. And one last one. I mean, the way I understand it, some of the officers in these companies, right, work also at the group level. They are part of the managers team, if I'm not wrong. I'm just trying to understand, you know, when when shareholders are looking at the talk about the pipeline, right, sometimes the pipeline is a number that's at the Chicago Atlantic group level. And some of that's going to get allocated to our new fundings, we allocated to the group, private group, to the mortgage REIT or maybe now to the BDC. That's also a publicly listed vehicle. Can you talk about how does the allocation process work in practice?

Chicago Atlantic personnel are equal fiduciaries to each of our funds. And more core, all opportunities that arise are given equal opportunity to be funded by each of the funds. That being said, any one of the funds, including the REIT, may decline to participate in a deal if it does not meet the requirements of the vehicle diversification requirements or other limitations that might make it ineligible for participation. And so it's challenging during the evaluation of an opportunity until near the end of the process to have certainty of what of what amount of the pipeline or what amount of a specific deal would be eligible and allocatable and expected to be allocated to one vehicle or another, whether that is the mortgage REIT, the BDC or or another vehicle. And that's that that is the reason why we provide a total pipeline number and not a more specific vehicle specific pipeline number.

Got it. Thank you very much.

Thank you. There appears to be no additional questions. This concludes our question and answer session. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.